Melphalan Aspen

Melphalan, the active ingredient in Melphalan Aspen, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma, ovarian cancer, melanoma and cervical cancer.

GNH USA supplies Melphalan Aspen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to hospitals, pharmacies and clinical trial sites across multiple regions. All shipments are accompanied by full documentation to ensure compliance with local import requirements.

Melphalan is used as an antineoplastic agent targeting rapidly dividing cells in several cancer types. - Multiple myeloma: Reduces tumor burden and prolongs survival in patients with this plasma‑cell malignancy. - Ovarian cancer: Used in combination regimens to improve response rates in advanced disease. - Melanoma: Provides cytotoxic activity against metastatic lesions resistant to other therapies. - Cervical cancer: Contributes to tumor control when incorporated into multimodal treatment protocols.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: Gastrointestinal upset commonly reported during treatment. - Fatigue: Generalized tiredness affecting daily activities. - Myelosuppression: Decreased blood cell counts leading to anemia or infection risk. - Alopecia: Temporary hair loss on scalp and body. - Mucositis: Inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Secondary malignancies: Development of new cancers after prolonged exposure. - Severe neutropenia: Marked reduction in neutrophils increasing infection susceptibility. - Pulmonary fibrosis: Scarring of lung tissue causing respiratory impairment. - Renal toxicity: Impaired kidney function manifesting as elevated creatinine.

When prescribing Melphalan, clinicians should observe several safety measures to minimize risks. - Baseline blood work: Obtain complete blood count and renal function before initiating therapy. - Monitor hematology: Perform regular CBCs to detect myelosuppression early. - Adjust for renal impairment: Reduce dose or increase interval in patients with decreased kidney function. - Avoid in active infection: Defer treatment until infection is controlled. - Counsel on contraception: Advise effective birth control during treatment and for a defined period after. - Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - CYP450 inducers: Drugs such as rifampin may lower melphalan plasma levels, reducing effectiveness. - High‑dose folate antagonists: Concurrent use can exacerbate myelosuppression.

Moderate Interactions (Monitor Closely): - Antiemetics containing steroids: May affect melphalan metabolism and increase infection risk. - NSAIDs: Can potentiate renal toxicity when combined with melphalan. - Live vaccines: Immunosuppression from melphalan may increase risk of vaccine‑derived infection. - Anticoagulants: Enhanced bleeding risk due to possible platelet count reductions.